Sign In
Buy MRNS
$0.550
+0 (+0%)
At Close: May 09, 2025
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates
09:35pm, Thursday, 12'th May 2022 Zacks Investment Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 40.23% and 548.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stoc
Marinus Pharmaceuticals, Inc. (MRNS) CEO Scott Braunstein on Q1 2022 Results - Earnings Call Transcript
08:11pm, Thursday, 12'th May 2022
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS ) Q1 2022 Earnings Conference Call May 12, 2022 4:00 PM ET Company Participants Sasha Damouni Ellis - VP, Corporate Communications, and IR Scott Braunstein -
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates
06:48pm, Thursday, 12'th May 2022
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 40.23% and 548.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stoc
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
12:42pm, Thursday, 12'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
BridgeBio Pharma Inc
Corcept Therapeutics (CORT) Misses Q1 Earnings and Revenue Estimates
10:05pm, Thursday, 05'th May 2022 Zacks Investment Research
Corcept (CORT) delivered earnings and revenue surprises of -13.04% and 5.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Marinus Pharmaceuticals (MRNS) to Report a Decline in Earnings: What to Look Out for
07:00pm, Thursday, 05'th May 2022 Zacks Investment Research
Marinus Pharmaceuticals (MRNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Marinus Pharmaceuticals (MRNS) to Report a Decline in Earnings: What to Look Out for
04:33pm, Thursday, 05'th May 2022
Marinus Pharmaceuticals (MRNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
07:16pm, Friday, 01'st Apr 2022 Benzinga
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
03:19pm, Friday, 01'st Apr 2022
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it
Marinus (MRNS) Gets FDA Nod for Ztalmy in Rare Genetic Disorder
01:52pm, Monday, 21'st Mar 2022 Zacks Investment Research
The FDA approves Marinus' (MRNS) Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. The company's shares gain following the announcement.
Marinus Pharmaceuticals, Inc. (MRNS) CEO Dr. Scott Braunstein on Q4 2021 Results - Earnings Call Transcript
01:43pm, Monday, 21'st Mar 2022
Marinus Pharmaceuticals, Inc. (MRNS) CEO Dr. Scott Braunstein on Q4 2021 Results - Earnings Call Transcript
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Misses Revenue Estimates
12:25pm, Monday, 21'st Mar 2022 Zacks Investment Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 4.94% and 42.42%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto
Marinus (MRNS) Gets FDA Nod for Ztalmy in Rare Genetic Disorder
11:17am, Monday, 21'st Mar 2022
The FDA approves Marinus' (MRNS) Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. The company's shares gain following the announcement.
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Misses Revenue Estimates
09:47am, Monday, 21'st Mar 2022
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 4.94% and 42.42%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto
Sigilon Therapeutics, Inc. (SGTX) Reports Q4 Loss, Misses Revenue Estimates
09:55pm, Monday, 14'th Mar 2022 Zacks Investment Research
Sigilon Therapeutics, Inc. (SGTX) delivered earnings and revenue surprises of -19.57% and 47.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for th
